| 1 |
35504655 | Understanding Inter-individual Variability in the Drug Interaction of a Highly Extracted CYP1A2 Substrate Tizanidine: Application of a Permeability-limited Multi-compartment Liver Model in a Population Based PBPK Framework. | 2022 May 3 |
5 |
| 2 |
33404754 | Coadministration of tizanidine and ciprofloxacin: a retrospective analysis of the WHO pharmacovigilance database. | 2021 Jun |
1 |
| 3 |
33561738 | Physiologically based pharmacokinetic modeling of altered tizanidine systemic exposure by CYP1A2 modulation: Impact of drug-drug interactions and cigarette consumption. | 2021 Apr |
6 |
| 4 |
32311241 | Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine (a CYP1A2 Substrate) in Patients With BRAFV600 Mutation-Positive Malignancies. | 2020 Jul |
1 |
| 5 |
33302490 | A Physiologically-Based Pharmacokinetic (PBPK) Model Network for the Prediction of CYP1A2 and CYP2C19 Drug-Drug-Gene Interactions with Fluvoxamine, Omeprazole, S-mephenytoin, Moclobemide, Tizanidine, Mexiletine, Ethinylestradiol, and Caffeine. | 2020 Dec 8 |
1 |
| 6 |
30223305 | Co-Prescription of Strong CYP1A2 Inhibitors and the Risk of Tizanidine-Associated Hypotension: A Retrospective Cohort Study. | 2019 Mar |
3 |
| 7 |
27318879 | Prediction of inter-individual variability on the pharmacokinetics of CYP1A2 substrates in non-smoking healthy volunteers. | 2016 Aug |
1 |
| 8 |
23370523 | [Clinical survey of tizanidine-induced adverse effects--impact of concomitant drugs providing cytochrome P450 1A2 modification--]. | 2013 |
4 |
| 9 |
19789372 | Effects of mexiletine, a CYP1A2 inhibitor, on tizanidine pharmacokinetics and pharmacodynamics. | 2010 Mar |
1 |
| 10 |
19961320 | Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2. | 2010 May |
1 |
| 11 |
19590965 | Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2. | 2009 Sep |
1 |
| 12 |
19754423 | Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. | 2009 |
1 |
| 13 |
17955229 | Effects of gender and moderate smoking on the pharmacokinetics and effects of the CYP1A2 substrate tizanidine. | 2008 Jan |
2 |
| 14 |
18816299 | In vitro inhibition of CYP1A2 by model inhibitors, anti-inflammatory analgesics and female sex steroids: predictability of in vivo interactions. | 2008 Aug |
1 |
| 15 |
17618427 | Tolfenamic acid is a potent CYP1A2 inhibitor in vitro but does not interact in vivo: correction for protein binding is needed for data interpretation. | 2007 Sep |
1 |
| 16 |
16934051 | Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjects. | 2006 Sep |
1 |
| 17 |
16985100 | Rofecoxib is a potent, metabolism-dependent inhibitor of CYP1A2: implications for in vitro prediction of drug interactions. | 2006 Dec |
1 |
| 18 |
16198659 | Oral contraceptives containing ethinyl estradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2. | 2005 Oct |
2 |
| 19 |
14998432 | Tizanidine is mainly metabolized by cytochrome p450 1A2 in vitro. | 2004 Mar |
3 |
| 20 |
15060511 | Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interaction. | 2004 Apr |
2 |
| 21 |
15592331 | Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism. | 2004 Dec |
3 |